Medtronic Becomes First and Only Company Globally to Receive FDA Label Approval Removing rAAA Treatment Warning for Endurant Stent Graft System
Medtronic
Medical Device Manufacturer
Recently, the giant Medtronic (New York Stock Exchange code:MDT) Announced,ItsEndurantThe covered stent system has successfully obtained approval from the U.S. Food and Drug Administration (FDA) for the new label approval, becoming the world's first and currently only company to remove rupture from the instructions for use of abdominal aortic aneurysms.（rAAA）Warning: Covered Stent.
The approval of the new label is of great significance, with the most crucial aspect being the addition of information regarding ruptured abdominal aortic aneurysms (rAAA) clinical evidence, while removing the previous content regardingrAAATreatment Warning. Medtronic emphasized that, with this approval, the company has become the world's first and currently only company to remove the instructions for use of stent grafts.rAAAWarning to companies. This change has a profound impact on doctors' clinical decision-making in emergency situations, making it so that doctors facerAAAPatients are able to take action with greater confidence.
Rupture of an abdominal aortic aneurysm is an extremely critical medical condition. The main artery in the abdomen——When the abdominal aorta ruptures, it will causerAAA。This condition can lead to severe internal bleeding in patients, with rapid progression, often necessitating urgent surgical intervention. According to relevant data and a press release issued by Medtronic, the mortality rate for ruptured abdominal aortic aneurysms is extremely high, exceeding80%. In such an urgent and high-risk situation, effective treatment methods are particularly crucial, andEndurantThe approval of the new label for the covered stent system provides doctors with a new treatment option in these critical moments.
Medtronic, as one of the largest medical technology companies in the world, has deep expertise and an outstanding reputation in the field of vascular therapy.EndurantThe covered stent system is one of the company's key products, with a research and development history and application exceeding ten years. The system primarily utilizes minimally invasive endovascular repair (EVAR) method to treat abdominal aortic aneurysm (AAA）。It is worth mentioning that,EndurantThe覆膜支架系统is the first and currently the only one with a decade of global registration achievements.EVARSystem, which fully demonstrates its stability and reliability in long-term clinical applications.
For thisEndurantThe approval of the new label for the covered stent system has been highly praised by experts in the medical field.Adam BeckDr., currently the director of the Department of Vascular Surgery and Endovascular Therapy at the University of Alabama, stated: "The new label allows doctors to have confidence for the first time in...rAAAThe choice of endovascular treatment for patients is made with confidence." This assessment highlights the significant guiding role of the new label in clinical practice, providing doctors with clear direction when facing complex and urgent situations.rAAAProvides a more solid basis for the case.
Vice President and General Manager of Aortic Division, Medtronic Cardiovascular PortfolioSimona ZannettiDr. stated in regard to this approval: "This significantFDALabel Approval CertificateEndurantThe innovation, durability, and effectiveness behind the covered stent system. We are proud to be the first in the industry to receive support.rAAA"The company's approval for the treatment label enhances our ability to support doctors in confidently treating patients in critical situations." Her words reflect Medtronic's confidence in the innovation and clinical value of its products, as well as the company’s commitment to continuously providing higher-quality solutions for the healthcare industry and patients.
This time, MedtronicEndurantStent Graft System ObtainedFDAThe approval of the new label is not only an important milestone in the development process of the company's products, but also for the globalrAAAThe treatment for patients brings new hope and options, with the potential to save more lives in future clinical practice.
More exciting content
Welcome to follow WeChat Video Channel
Ramping Up in China, ZEISS Achieves the Industry's First
ConvaTech Medical will be delisted in December
GE Healthcare Enters New Imaging Track
860 Million! MGI Achieves China's First Medical Device IP Export
Zhejiang Province's Top 1 Hospital, Ultra-Long Treasury Bonds Spark Demand
"CDC is Done"? Over 1,000 Experts Laid Off
A-share Medical Device Leader: Products Banned from U.S. Market
This product, Level 1 recall 4 times in March
Roche to Expand Layout in China
Abbott Acquires Artificial Intelligence Imaging Company
BusinessBusiness cooperation email: qxzj@landianyiliao.com
